Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer

PI3K 抑制剂与 PARP 抑制剂联合使用可为 BRCA1 相关乳腺癌提供有效治疗

阅读：9

作者：Ashish Juvekar, Laura N Burga, Hai Hu, Elaine P Lunsford, Yasir H Ibrahim, Judith Balmañà, Anbazhagan Rajendran, Antonella Papa, Katherine Spencer, Costas A Lyssiotis, Caterina Nardella, Pier Paolo Pandolfi, José Baselga, Ralph Scully, John M Asara, Lewis C Cantley, Gerburg M Wulf

期刊：

Cancer Discovery

影响因子：

29.700

时间：

2012

起止号：

2012 Nov;2(11):1048-63.

doi：

10.1158/2159-8290.CD-11-0336

研究方向：

信号转导、肿瘤

疾病类型：

乳腺癌

信号通路：

PI3K/Akt

Significance

Current treatment options for triple-negative breast cancer are limited to chemotherapeutic regimens that have considerable toxicity and are not curative. We report here that the combination of a PI3K inhibitor with a PARP inhibitor provides in vivo synergy for treatment of an endogenous mouse model for BRCA1-related breast cancers, making this a candidate combination to be tested in human clinical trials.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。